NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Wednesday, March 26th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter.
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last posted its quarterly earnings results on Friday, March 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). On average, analysts expect NRx Pharmaceuticals to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.
NRx Pharmaceuticals Stock Up 7.3 %
NASDAQ NRXP opened at $2.20 on Wednesday. The company has a 50-day simple moving average of $2.94 and a two-hundred day simple moving average of $2.02. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $6.01. The firm has a market cap of $37.22 million, a price-to-earnings ratio of -1.03 and a beta of 1.22.
Analyst Upgrades and Downgrades
Read Our Latest Report on NRx Pharmaceuticals
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.
Read More
- Five stocks we like better than NRx Pharmaceuticals
- Conference Calls and Individual Investors
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- What is a Death Cross in Stocks?
- 3 Must-Own Stocks to Build Wealth This Decade
- What is the S&P 500 and How It is Distinct from Other Indexes
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.